Skip to main content
. 2022 Mar 14;8:114. doi: 10.1038/s41420-022-00915-8

Fig. 2. GSDMD increases the cisplatin chemosensitivity of cells through a non-pyroptotic way.

Fig. 2

A ELISA assays showing the release of IL-1β of Cal-27 and SCC-9 cells treated with cisplatin for 24 h. B LDH-cytotoxicity experiments showing the LDH release in control and GSDMD-overexpressing cells after cisplatin treatment (24 h). The GSDME-overexpressing cells serve as a positive control. C Western blot showing the absence of cleavage of GSDMD in control and GSDMD-overexpressing cells after cisplatin treatment (24 h). D Representative images of high-content microscopy live imaging showing the changes of cell morphology after cisplatin treatment. It showed that cells with empty vector and wild-type GSDMD vector did not undergo typical pyroptosis after cisplatin treatment (shown by the blue arrow in the figure), while cells overexpressing GSDME and mutant GSDMD showed typical balloon-like swelling death (shown by the red arrow in the figure). E Flow-cytometry assays showing cell death of control and GSDMD-overexpressing Cal-27 cells after cisplatin treatment (24 h). DMF was used as a specific inhibitor of pyrolysis. F The statistical-analysis result of flow cytometry assays. G Western blot showing the expression and cleavage of caspase-1 and caspase-3. H The qPCR showing the expression of NLRP-3, NLRP12 and TLR7 in head and neck squamous- (Cal-27 and SCC-9), cervical cancer (HeLa) and monocyte (THP-1) cell lines.